 <h1>Calquence Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>acalabrutinib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about acalabrutinib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Calquence.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to acalabrutinib: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, acalabrutinib (the active ingredient contained in Calquence) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking acalabrutinib:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding gums</li>
<li>collection of blood under the skin</li>
<li>coughing up blood</li>
<li>difficulty in breathing or swallowing</li>
<li>dizziness</li>
<li>headache</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>itching, pain, redness, or swelling</li>
<li>large, flat, blue or purplish patches in the skin</li>
<li>nosebleeds</li>
<li>paralysis</li>
<li>prolonged bleeding from cuts</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of acalabrutinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
<li>diarrhea</li>
<li>difficulty in moving</li>
<li>joint pain or swelling</li>
<li>muscle cramp, pain, or stiffness</li>
<li>nausea</li>
<li>rash</li>
<li>stomach pain</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to acalabrutinib: oral capsule</i></p><h3>General</h3><p>The most common adverse reactions (reported incidence of 20% or greater) were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Bleeding events (50%)</p>
<p><b>Common</b> (1% to 10%): Hemorrhage/hematoma</p>
<p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation, atrial flutter<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased hemoglobin (46%), decreased platelets (44%), decreased neutrophils (36%), neutropenia (23%), anemia (11%)</p>
<p><b>Common</b> (1% to 10%): Thrombocytopenia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (39%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (31%), nausea (19%), abdominal pain (15%), constipation (15%), vomiting (13%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Bruising/petechiae/ecchymosis/contusion (21%), rash (18%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (21%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Very common</b> (10% or more): Second primary malignancies (11%)</p>
<p><b>Common</b> (1% to 10%): Skin cancer<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased creatinine<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Epistaxis</p>
<p><b>Frequency not reported</b>: Pneumonia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (28%)</p>
<p><b>Frequency not reported</b>: Infections<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the names of the BTK inhibitors?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Calquence (acalabrutinib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: BTK inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Calquence &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Lymphocytic Leukemia</li>
<li>Mantle Cell Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to acalabrutinib: oral capsule</i></p><h3>General</h3><p>The most common adverse reactions (reported incidence of 20% or greater) were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Bleeding events (50%)</p><p><b>Common</b> (1% to 10%): Hemorrhage/hematoma</p><p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation, atrial flutter<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased hemoglobin (46%), decreased platelets (44%), decreased neutrophils (36%), neutropenia (23%), anemia (11%)</p><p><b>Common</b> (1% to 10%): Thrombocytopenia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (39%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (31%), nausea (19%), abdominal pain (15%), constipation (15%), vomiting (13%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Bruising/petechiae/ecchymosis/contusion (21%), rash (18%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (21%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Very common</b> (10% or more): Second primary malignancies (11%)</p><p><b>Common</b> (1% to 10%): Skin cancer<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased creatinine<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Epistaxis</p><p><b>Frequency not reported</b>: Pneumonia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (28%)</p><p><b>Frequency not reported</b>: Infections<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the names of the BTK inhibitors?</li>
</ul><h2>More about Calquence (acalabrutinib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: BTK inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Calquence &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Lymphocytic Leukemia</li>
<li>Mantle Cell Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>